Erol Onel

Erol Onel
Pacira Pharmaceuticals

About

52
Publications
8,966
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,796
Citations
Introduction
Skills and Expertise
Additional affiliations
July 2006 - June 2008
July 1999 - June 2005
New England Baptist Hospital
Position
  • New England Medical Center

Publications

Publications (52)
Poster
Full-text available
Synergistic Effect of Bupivacaine and Meloxicam in HTX-011 Across Multiple Doses and Surgeries
Poster
Full-text available
HTX-011, a Locally Administered Analgesic, Reduces Postoperative Pain Intensity and Opioid Use Through 72 Hours Across Bony and Soft Tissue Surgical Models
Poster
Full-text available
Synergistic Effect of Bupivacaine and Meloxicam in HTX-011: Animal and Clinical Studies
Poster
Full-text available
HTX-011, a Proprietary, Extended-Release Synergistic Combination of Bupivacaine and Meloxicam for the Relief of Acute Postoperative Pain
Poster
Full-text available
HTX-011, a Proprietary, Extended-Release Combination of Bupivacaine and Meloxicam, Reduced Pain Intensity and Opioid Consumption for 96 Hours Following Abdominoplasty
Article
Background/objective: Bupivacaine liposome injectable suspension is a novel, prolonged-release formulation of bupivacaine. The time to onset of analgesia following an injection of liposome bupivacaine compared with placebo (normal saline) was investigated using a novel incisional pain model. Bupivacaine HCl was used as a positive control, compared...
Article
Background: Liposome bupivacaine is a liposomal formulation that allows delivery of bupivacaine for 96 hours with a single local administration. It is indicated for the management of postsurgical pain. Objective: This retrospective review of 10 clinical trials assessed the potential impact of local anesthetics on wound healing and chondrolysis....
Article
Objective: Pooled safety data from 10 randomized, double-blind studies of liposome bupivacaine, a novel local analgesic formulation, were examined. Methods: Eight hundred twenty-three patients received liposome bupivacaine (dose, 66 to 532 mg) given locally at the surgical site in 5 different settings (hemorrhoidectomy, bunionectomy, breast augm...
Article
Local anaesthetics are often used as part of multimodal pain management techniques to manage postsurgical pain and lessen the need for opioid analgesics; however, the duration of action of traditional formulations of local anaesthetics is short. Liposome bupivacaine is a novel, multivesicular formulation designed for rapid absorption, prolonged rel...
Article
The objective of this study was to assess the pharmacokinetics, sensory/motor effects, and safety of epidurally administered liposome bupivacaine versus bupivacaine HCl in healthy volunteers. Thirty subjects were randomized to receive liposome bupivacaine 89, 155, or 266 mg, or bupivacaine HCl 50 mg in a double-blind fashion. Occurrence/duration of...
Article
Full-text available
This randomized, active-controlled study evaluated the extent and duration of analgesia after administration of liposome bupivacaine (LB), a novel formulation of bupivacaine, compared with bupivacaine HCl given via local infiltration in excisional hemorrhoidectomy. One hundred patients were randomly assigned to receive a single dose of bupivacaine...
Article
Full-text available
Bupivacaine extended-release liposome injection is an investigational local analgesic intended for use in postsurgical pain management. In recognition of the incompletely characterized association of bupivacaine use and cardiac effects, this article reviews the cardiac safety profile of this novel formulation of bupivacaine. Findings from paired el...
Article
Full-text available
Two-year safety outcomes in patients who received DepoFoam bupivacaine during two prior breast augmentation studies were evaluated. The authors assess the clinical sequelae observed during follow-up examination with respect to the integrity of the breast implants. In Study 1, patients received bupivacaine HCl (75 mg) in one breast pocket and DepoFo...
Article
DepoFoam bupivacaine is a novel liposomal formulation of bupivacaine designed to provide prolonged postsurgical analgesia. This dose-ranging study evaluated extent and duration of analgesia following administration of DepoFoam bupivacaine in patients undergoing total knee arthroplasty (TKA). Efficacy, safety, and pharmacokinetics of DepoFoam bupiva...
Article
Full-text available
Breast augmentation can result in significant postsurgical pain. The authors evaluate the extent and duration of analgesia achieved with extended-release DepoFoam bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty under general anesthesia. In this rando...
Article
Bupivacaine extended-release liposome injection is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia. The aim of this study was to compare the magnitude and duration of postoperative analgesia from a single dose of bupivacaine extended-release injection with placebo administered intraoperatively in patients...
Article
Full-text available
SUMMARY An extended-release, multivesicular liposome-encapsulated form of the local anesthetic bupivacaine, DepoFoam(®) bupivacaine (proposed proprietary name EXPAREL™), is in development for use as part of a multimodal regimen for the treatment of postsurgical pain. Placebo- and active-controlled clinical trials in patients who have undergone eith...
Article
DepoFoam® bupivacaine (Pacira Pharmaceuticals, Inc., San Diego, CA, USA), an extended-release liposomal bupivacaine-based analgesic, was compared with placebo for the prevention of pain after bunionectomy in a randomized, multicenter, double-blind phase 3 clinical study. Patients received placebo (n = 96) or DepoFoam bupivacaine 120 mg (n = 97) via...
Article
Full-text available
No studies have evaluated the efficacy of hyaluronic acid (HA) in reducing pain caused by osteochondritis dissecans (OCD) of the ankle. We report our initial results with this treatment. Fifteen subjects aged 18 to 60 treated for OCD of the talus were followed for 26 weeks, in a pre- and post-treatment repeated measurements design, after receiving...
Article
16002 Background: Several formulations of Luteinizing Hormone-Releasing Hormone Agonists (LHRH-A) of varying duration are available for treatment of prostate cancer (PCa). Previous reports suggest that utilization of longer acting LHRH-A may reduce the number of healthcare visits, thereby reducing the costs of managing PCa patients. In this study w...
Article
Several intra-articular hyaluronic acid products are available for treating osteoarthritis (OA) of the knee, including hylan G-F 20 and the bioengineered straight-chain hyaluronic acid (Bio-HA). A recently published study in patients with knee OA demonstrated non-inferiority with regard to efficacy, using the pain subscore of the Western Ontario an...
Article
To investigate the effect of lower urinary tract symptoms (LUTS) on quality of life (QoL) and to determine its extent across a variety of cultures, and the confounding effects of self-reported comorbidities and demographics. Data were obtained from two population-based studies in five cities: UREPIK (Boxmeer, the Netherlands; Auxerre, France; Birmi...
Article
Purpose: We used an infrared ureteral stent to aid in laparoscopic retroperitoneal lymph node dissection. Materials and methods: The patient was slender 31-year-old male. An infrared light emitting stent was used. Results: With easy visualization of the ureter laparoscopic retroperineal lymph node dissection required 268 minutes. Conclusions:...
Article
To assess the feasibility and patient impact of using standardized video presentations concerning alternative treatments for managing localized prostate cancer. One hundred eleven men with newly diagnosed localized prostate cancer were shown a video tape concerning the risks and benefits of four treatment options: radical surgery, external beam rad...
Article
To determine the prevalence of cystic lesions of the prostate involving the ejaculatory ducts using transrectal ultrasound (TRUS). The prevalence of cystic lesions of the prostate involving the ejaculatory ducts was determined in a prostate cancer screening group and also in an "at risk" population of men with infertility. Cystic lesions of the pro...
Article
To the Editor. —If a patient were to request a specific medication (perhaps having seen it in a television advertisement) that you thought was not only unnecessary but actually contraindicated, would you feel obliged to comply? What if the patient had written and signed a directive stating explicitly that in the event of an illness, that medicatio...

Network

Cited By